Glaucoma News

BOSTON — Phacoemulsification plus minimally invasive glaucoma surgery improves quality of life and prevents visual field loss in patients with glaucoma, according to a speaker.

Patients with glaucoma who underwent cataract surgery in combination with the Omni surgical system had lower IOP and used fewer medications at 24 months compared with outcomes with other devices, according to a study.

BOSTON — In this Healio Video Perspective from the ASCRS meeting, Cody McKenzie of Glaukos discusses the anticipated impact of the iDose TR, which launched during the meeting.

More than half of all patients treated with glaucoma medications have ocular surface disease, which predominantly manifests as dry eye disease.

BOSTON — In this Healio Video Perspective from Eyecelerator@ASCRS, Pete England, vice president of global marketing at ViaLase, discusses the company’s femtosecond laser platform for the treatment of open-angle glaucoma.

TAMPA, Fla. — In a presentation from Telling It Like It Is, Analisa Arosemena, MD, discussed the path to achieving 24/7 IOP control for patients with glaucoma and the role that canaloplasty may play.

Qlaris Bio announced the initiation and dosing of two phase 2 trials aimed at assessing QLS-111, a therapy for lowering intraocular pressure by targeting episcleral venous pressure, or EVP, in patients with glaucoma.

ViaLase has secured approximately $40 million in Series C financing to drive the continued development of the company’s femtosecond laser for the treatment of glaucoma, according to a press release.

The first quarter of 2024 has come to a close, but Healio’s ophthalmology meeting news coverage is just getting started.

In this episode, John A. Hovanesian, MD, FACS, and Jim Mazzo discuss the latest news in eye care and chat with Wiley A. Chambers, MD, about his career in the FDA and his plans for retirement.